Back

Sai Parenterals Limited IPO: Business Model, Financials and Risks

25 Mar, 2026

3 mins read

The Sai Parenterals Limited IPO opened on March 24, 2026. Established as a diversified pharmaceutical formulations company, it has built a strong reputation in research, development, and manufacturing. While its legacy lies in injectable formulations, the company has successfully expanded into oral solids and established itself as a reliable Contract Development and Manufacturing Organisation (CDMO) partner for both domestic and international markets.

In this article, we break down the Sai Parenterals Ltd IPO details, business model, financial performance, and the key risks and opportunities for prospective investors.

Sai Parenterals Ltd IPO Details

Particulars	Details
IPO Date	March 24 to 27, 2026
Price Band	₹372 to ₹392 per share
Lot Size	38 Shares
Issue Size	₹409 crore
Fresh Issue	₹285 crore
Offer for Sale	₹124 crore
Listing On	NSE, BSE

Utilisation of IPO Proceeds

The company intends to use the Net Proceeds from the Fresh Issue for the following primary objectives:

Capacity Expansion: ₹110.8 crore for expanding and upgrading manufacturing facilities.
New R&D Centre: ₹18.0 crore for establishing a research facility.
Working Capital: ₹33.0 crore to meet day-to-day operational requirements.
Debt Repayment: ₹14.3 crore to settle certain outstanding borrowings.
Acquisition Funding: ₹35.6 crore for repayment of loans taken for the acquisition of Noumed Pharmaceuticals (Australia).

Financial Performance of Sai Parenterals Ltd

Particulars	H1 FY26 (6M)	FY25	FY24	FY23
Revenue from Operations (₹ Cr)	86.9	163.1	153.8	96.8
Profit After Tax (PAT) (₹ Cr)	7.8	14.5	8.4	4.4
PAT Margin (%)	8.9	8.9	5.5	4.5
EBITDA (₹ Cr)	16.2	39.4	31.7	17.6
EBITDA Margin (%)	18.7	24.2	20.6	18.2

Business Model of Sai Parenterals Ltd

Sai Parenterals operates a diversified model centered on two major pharmaceutical segments:

Branded Generic Formulations: This division contributes the majority of revenue (80.29% in FY25). It focuses on off-patent products sold under the company's own brand names, serving government agencies, hospitals, and retail super stockists.

CDMO Products & Services: Sai Parenterals provides end-to-end solutions from product development and stability studies to commercial manufacturing. This segment is high-growth, with revenue increasing from ₹5.32 crore in FY23 to ₹31.25 crore in FY25.

The company operates five manufacturing facilities in India. Recent strategic moves include the 74.64% acquisition of Noumed Pharmaceuticals (Australia), which provides access to 451 TGA-approved dossiers and a footprint in the Australian and New Zealand markets.

Opportunities and Risks

Sai Parenterals presents promising opportunities, but it also comes with risks that investors should evaluate carefully.

Opportunities

Global Expansion: The acquisition of Noumed significantly strengthens the company's export footprint in regulated markets like Australia.
Diversified Dosage Forms: Capabilities spanning injectables, tablets, capsules, and liquid orals allow for broad therapeutic reach.
R&D Focused Growth: The plan to establish a new R&D center is expected to accelerate the commercialisation of complex generics.

Risks

Negative Operating Cash Flows: The company has experienced negative cash flows in past periods due to high working capital requirements.
Raw Material Dependency: The company lacks long-term contracts for raw materials like APIs and excipients, making it vulnerable to price fluctuations and supply disruptions.
Geographic Concentration: Manufacturing is heavily concentrated in Telangana and Andhra Pradesh, making it sensitive to regional disruptions.

Bottom Line

Sai Parenterals presents an evolving investment story, transitioning from a pure-play injectable manufacturer to a global pharmaceutical specialist with a growing CDMO portfolio. The strategic acquisition in Australia signals a high-margin growth path, though investors must weigh this against the company's working capital challenges and ongoing regulatory environment.

Eligible investors can apply for the IPO through ASBA-enabled brokers, including via the FYERS platform.

Disclaimer: This blog is for educational and informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Conduct your own research or consult a financial advisor before applying.